文献速递消化系统肿瘤

结直肠癌腹膜转移患者的生存受诊断医院治疗差异影响:一项全国性人群研究

Survival of patients with colorectal peritoneal metastases is affected by treatment disparities among hospitals of diagnosis: A nationwide population-based study.
PubMed 文献 · Eur J Cancer · 2017-02-20

该研究基于荷兰癌症登记2005至2015年数据,纳入2661例在89家医院诊断的同步性结直肠癌腹膜转移无全身转移患者。诊断医院类型影响细胞减灭术联合腹腔热灌注化疗(CRS/HIPEC)的选择及总生存(OS)。结论认为诊断医院间的治疗差异及其对生存的影响提示PMCRC治疗选择欠佳。

要点

  • 诊断于HIPEC中心的患者接受CRS/HIPEC的比例为33%,转诊医院为13%(OR 3.66 [2.40-5.58])
  • HIPEC中心诊断者中位OS为14.1个月,转诊医院为9.6个月(HR 0.82 [0.67-0.99])
  • 与非教学医院相比,学术/教学医院诊断者接受CRS/HIPEC的可能性更高(11% vs 17%,OR 0.60 [0.47-0.77])

核心结论

  • 诊断医院间的治疗差异及其对生存的影响提示结直肠癌腹膜转移的治疗选择欠佳。

研究设计与样本

  • 研究基于荷兰癌症登记2005至2015年数据,纳入2661例在89家医院诊断的同步性结直肠癌腹膜转移无全身转移患者。
  • 治疗分为细胞减灭术联合腹腔热灌注化疗(CRS/HIPEC)、全身治疗或其他/无治疗;诊断医院按非教学/学术教学医院及HIPEC中心/转诊医院分类,转诊医院再按CRS/HIPEC频率分为高、中、低频医院。
  • 采用多因素回归分析评估医院类别对CRS/HIPEC可能性及总生存(OS)的独立影响。

主要发现

  • 个体医院水平上,CRS/HIPEC比例范围为0%至50%,全身治疗比例范围为6%至67%。
  • HIPEC中心诊断者接受CRS/HIPEC的比例为33%,转诊医院为13%(OR 3.66 [2.40-5.58]);非教学医院为11%,学术/教学医院为17%(OR 0.60 [0.47-0.77])。
  • HIPEC中心诊断者中位OS为14.1个月,转诊医院为9.6个月(HR 0.82 [0.67-0.99]);非教学医院为8.7个月,学术/教学医院为11.5个月(HR 1.15 [1.06-1.26])。
  • 与中频转诊医院诊断者相比,高频转诊医院诊断者中位OS延长至12.6个月(HR 0.82 [0.73-0.91]),低频转诊医院诊断者中位OS缩短至8.1个月(HR 1.12 [1.01-1.24])。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the Netherlands, surgery for peritoneal metastases of colorectal cancer (PMCRC) is centralised, whereas PMCRC is diagnosed in all hospitals. This study assessed whether hospital of diagnosis affects treatment selection and overall survival (OS). METHODS: Between 2005 and 2015, all patients with synchronous PMCRC without systemic metastases were selected from the Netherlands Cancer Registry. Treatment was classified as cytoreductive surgery with hyperthermic intraperitoneal chemotherapy (CRS/HIPEC), systemic therapy or other/no treatment. Hospitals of diagnosis were classified as: (1) non-teaching or academic/teaching hospital and (2) HIPEC centre or referring hospital. Referring hospitals were further classified based on the frequency of CRS/HIPEC as high-, medium- or low-frequency hospital. Multivariable regression analyses were used to assess the independent influence of hospital categories on the likelihood of CRS/HIPEC and OS. RESULTS: A total of 2661 patients, diagnosed in 89 hospitals, were included. At individual hospital level, CRS/HIPEC and systemic therapy ranged from 0% to 50% and 6% to 67%, respectively. Hospital of diagnosis influenced the likelihood of CRS/HIPEC: 33% versus 13% for HIPEC centres versus referring hospitals (odds ratio (OR) 3.66 [2.40-5.58]) and 11% versus 17% for non-teaching hospitals versus academic/teaching hospitals (OR 0.60 [0.47-0.77]). Hospital of diagnosis affected median OS: 14.1 versus 9.6 months for HIPEC centres versus referring hospitals (hazard ratio (HR) 0.82 [0.67-0.99]) and 8.7 versus 11.5 months for non-teaching hospitals versus academic/teaching hospitals (HR 1.15 [1.06-1.26]). Compared with diagnosis in medium-frequency referring hospitals, median OS was increased in high-frequency referring hospitals (12.6 months, HR 0.82 [0.73-0.91]) and reduced in low-frequency referring hospitals (8.1 months, HR 1.12 [1.01-1.24]). CONCLUSION: Treatment disparities among hospitals of diagnosis and their impact on survival indicate suboptimal treatment selection for PMCRC.

来源:Eur J Cancer,查看原文。版权归原作者所有。

引用

  1. Rovers KP, Simkens GA, Vissers PA, et al. Survival of patients with colorectal peritoneal metastases is affected by treatment disparities among hospitals of diagnosis: A nationwide population-based study. Eur J Cancer. 2017. PMID: 28222307. doi:10.1016/j.ejca.2016.12.034

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。